Australia markets open in 2 hours 43 minutes
  • ALL ORDS

    7,000.60
    -67.30 (-0.95%)
     
  • AUD/USD

    0.7726
    -0.0052 (-0.67%)
     
  • ASX 200

    6,760.70
    -57.30 (-0.84%)
     
  • OIL

    64.19
    +2.91 (+4.75%)
     
  • GOLD

    1,695.90
    -19.90 (-1.16%)
     
  • BTC-AUD

    61,749.72
    -4,497.05 (-6.79%)
     
  • CMC Crypto 200

    955.07
    -32.14 (-3.26%)
     

Respiratory Syncytial Virus Therapeutics Market worth USD 4,003.4 Million at 30.9% CAGR; Varying Ethnicity and Climate Difference to Boost Demand in Asia Pacific

Fortune Business Insights
·9-min read

Key Prominent Players Covered in the Respiratory Syncytial Virus Therapeutics Market Research Report Are AstraZeneca (U.K), Bausch Health Companies Inc. (U.S), AbbVie (U.S), Johnson and Johnson Services Inc. (U.S), Sanofi (France), Merck & Co., Inc. (U.S), Celltrion Inc. (South Korea), mAbxience (Spain), Enanta Pharmaceuticals, Inc. (U.S) and other key market players.

Pune, India, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The global Respiratory Syncytial Virus Therapeutics Market size is estimated to showcase potential growth owing to its increasing adoption against the prevention and treatment of the disease, observes Fortune Business Insights™ in an upcoming report, titled, “Respiratory Syncytial Virus Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027.” The Respiratory Syncytial Virus Therapeutics Market stood at USD 1,111.3 million in 2019. It is projected to grow from USD 609.2 million in 2020 to USD 4,003.4 million in 2027 at a CAGR of 30.9% in the forecast period.

High Production Scale to Hinder Growth Opportunities in Global Pharmaceutical Space

The COVID-19 contagion is expected to drive the global pharmaceutical industry. Enterprises across the world along with governments from several nations are contributing to the development and distribution of the vaccine. However, the scale at which the production is assumed to take place is a major challenge for most of the renowned players. At Fortune Business Insights™, we are providing actionable insights by closely studying multiple aspects of the current scenario. We are also offering firsthand information on various market trends through our comprehensive research reports.


Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/respiratory-syncytial-virus-rsv-therapeutics-market-104668


While making the report, we segmented the market on the basis of product, type, consumption, distribution channel, and region. Based on the segmentation, we made a list of companies and conducted a detailed analysis of their financial positions, product portfolios, and growth strategies. Our next step included the study of core competencies of key players and their market share to anticipate the degree of competition. The bottom-up procedure was conducted to arrive at the overall size of the market.

Mergers and Acquisitions to Help Enterprises Develop Effective Products

The rising adoption of preventive and treatment drugs among children against the disease is expected to drive the growth of the global RSV therapeutics market. In addition, collaborations among key players to develop cost efficient drugs for the treatment of RSV disease is anticipated to increase the demand globally, which is expected to further enhance growth. For instance, in January 2019, Swedish Orphan Biovitrum Ab acquired the distribution rights of Synagis, a respiratory syncytial virus prophylactic drug from AstraZeneca. However, failure of the pipeline drugs in the clinical trials is expected to limit growth.


To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/respiratory-syncytial-virus-rsv-therapeutics-market-104668


New Product Launches from Key Players Helped Prophylaxis Segment Hold Largest Share In 2019

Based on drug class, the prophylaxis segment led the market with the largest share in 2019. Potential approvals and launch of maternal vaccines by companies including Pfizer and GSK are estimated to help the segment further dominate the market during the forecast timeframe. Based on end-user, the hospital pharmacy segment dominated the global market owing to the high demand for healthcare professionals for the existing treatment and prevention options.

Growing Instances of RSV Infection among Infants in U.S. to Help North America Dominate

North America is anticipated to lead the global RSV therapeutics market owing to the higher prevalence of RSV infection in the region. For instance, as per the data published by the Center for Disease Control and Prevention (CDC), almost 2.1 million annual outpatient visits among children under five years of age in the U.S. are led by RSV infection. In addition, larger access for the treatment of the disease is expected to drive the demand for respiratory syncytial virus therapeutics in the region. The region held USD 396.0 million in terms of revenue in 2019.

The market in Asia Pacific is estimated to grow significantly in the upcoming years. Countries including Japan and Australia have advanced healthcare infrastructure combined with higher penetration of respiratory syncytial virus therapeutics. In addition, the varying ethnicity and climate creates a difference in the prevalence of RSV in various countries of the region.


Quick Buy - Respiratory Syncytial Virus Therapeutics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/104668


Introduction of Cost-effective Drugs to Aid Emerging Players Gain Share

Major players operating in the respiratory syncytial virus therapeutics market are focusing on gaining prominence in the industry through their development strategies. Key enterprises are focusing on new product launches in order to expand their share. For instance, AstraZeneca aims to capture the predominant share in the upcoming years with the introduction of cost-effective nirsevimab into the market by 2023.

Industry Developments-

  • In August 2020, Janssen Pharmaceutical Companies, a division of Johnson and Johnson Service, Inc. announced the reception of breakthrough designation for its RSV prophylactic vaccine by the US FDA. The designation was based on clinical data from Janssen's prophylactic RSV senior vaccine, which may act as potential improvement compared to the available standard of care.

  • In November 2018, AstraZeneca announced an agreement with Synagis to transfer its U.S. rights to Swedish Orphan Biovitrum AB (Sobi). According to the agreement, Sobi is set to commercialize Synagis in the U.S.


A List of Key Manufacturers Operating In the Global Respiratory Syncytial Virus Therapeutics Market Report:

  • AstraZeneca (U.K)

  • Bausch Health Companies Inc. (U.S)

  • AbbVie (U.S)

  • Johnson and Johnson Services Inc. (U.S)

  • Sanofi (France)

  • Merck & Co., Inc. (U.S)

  • Celltrion Inc. (South Korea)

  • mAbxience (Spain)

  • Enanta Pharmaceuticals, Inc. (U.S)


Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/respiratory-syncytial-virus-rsv-therapeutics-market-104668


Table of Contents:

  • Introduction

    • Research Scope

    • Market Segmentation

    • Research Methodology

    • Definitions and Assumptions

  • Executive Summary

  • Market Dynamics

    • Market Drivers

    • Market Restraints

    • Market Opportunities

  • Key Insights

    • Potential Vaccine Candidates and Potential Impact of Approvals on the Treatment Market

    • Trends: Changing Landscape Treatment & Prophylaxis, Unmet Needs, etc.

    • Total Number of Patients Receiving Palivizumab, Key Countries/ Region

    • Potential Vaccine Candidates and Potential Impact of Approvals on the Treatment Market

    • Trends: Changing Landscape Treatment & Prophylaxis, Unmet Needs, etc.

    • Total Number of Patients Receiving Palivizumab, Key Countries/ Region

    • Impact of Covid-19 on the Market

  • Global Respiratory Syncytial Virus Therapeutics Market Analysis, Insights and Forecast, 2016-2027

    • Key Findings / Summary

    • Market Analysis, Insights and Forecast – By Drug Class

      • Prophylaxis

        • Palivizumab

        • Nirsevimab

        • MK-1654

        • Other Prophylaxis (Vaccines)

      • Treatment

        • Ribavirin

        • All New Treatment

          • JNJ 53718678

          • Enanta EDP-938

          • ASCENIV

    • Market Analysis, Insights and Forecast – By End User

      • Hospital Pharmacies

      • Retail Pharmacies

      • Online Pharmacies

    • Market Analysis, Insights and Forecast – By Country

      • North America

      • Europe

      • Asia pacific

      • Latin America

      • Middle East & Africa


TOC Continued….!


Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/respiratory-syncytial-virus-rsv-therapeutics-market-104668


SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

  • Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies

  • Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.

  • Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility

  • Number of procedures and average price of procedures

  • Replacement rate and pricing of capital equipment

  • Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities

  • Market & technological trends, new product developments, product pipeline.


Have a Look at Related Reports:

Antiviral Drugs Market Share & Industry Analysis, By Drug Class (Protease Inhibitors, Polymerase Inhibitors, Integrase Inhibitors, Combination Drugs, Reverse Transcriptase Inhibitors, and Others), By Disease Indication (Hepatitis, Human Immunodeficiency Virus (HIV), Influenza, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Channel) and Regional Forecast, 2019-2026

Vagus Nerve Stimulation (VNS) Market Share & Industry Analysis, By Type (Invasive, and Non-invasive {nVNS}), By Application (Epilepsy, Treatment Resistant Depression (TRD), and Others), By End User (Hospitals, and Specialty Clinics), and Regional Forecast, 2019-2026

Spinal Muscular Atrophy (SMA) Treatment Market Share & Industry Analysis, By Product (Nusinersen and Onasemnogen Abeparvovec), By Disease Type (Type 1 SMA, Type 2 SMA and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), and Regional Forecast, 2019-2026

Venous Leg Ulcer (VLU) Treatment Market Share and Industry Analysis, By Product (Compression Therapy, Advanced Wound Dressings, Others), By End User (Hospitals, Specialty Clinics, Homecare Settings, Others), and Regional Forecast, till 2026

Animal Health Market Share and Industry Analysis By Product (Drugs, Vaccines, Feed, and Diagnostics), By Animal (Livestock Animals and Companion Animals), By End User (Veterinary Hospitals & Clinics, Animal Care & Rehabilitation Centers, Diagnostic Centers, and Others) and Geography Forecast, 2019-2026


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.


Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs


Press Release: https://www.fortunebusinessinsights.com/press-release/global-respiratory-syncytial-virus-therapeutics-market-10463